Format

Send to

Choose Destination
BJPsych Open. 2016 Mar 9;2(2):139-146. eCollection 2016 Mar.

The effect of second-generation antipsychotics on hippocampal volume in first episode of psychosis: longitudinal study.

Author information

1
, PhD, Prevention and Early Intervention Program for Psychoses (PEPP - Montreal), Douglas Mental Health University Institute, Montreal, Canada; Department of Psychology, McGill University, Montreal, Canada.
2
, MD, Prevention and Early Intervention Program for Psychoses (PEPP - Montreal), Douglas Mental Health University Institute, Montreal, Canada; Department of Psychiatry, McGill University, Montreal, Canada.
3
, BSc, Integrated Program in Neuroscience, McGill University, Montreal, Canada.
4
, PhD, Department of Psychiatry, McGill University, Montreal, Canada; Integrated Program in Neuroscience, McGill University, Montreal, Canada.
5
, MD, PhD, Prevention and Early Intervention Program for Psychoses (PEPP - Montreal), Douglas Mental Health University Institute, Montreal, Canada; Department of Psychiatry, McGill University, Montreal, Canada.
6
, PhD, Prevention and Early Intervention Program for Psychoses (PEPP - Montreal), Douglas Mental Health University Institute, Montreal, Canada; Department of Psychology, McGill University, Montreal, Canada; Department of Psychiatry, McGill University, Montreal, Canada; Integrated Program in Neuroscience, McGill University, Montreal, Canada.

Abstract

BACKGROUND:

Current neuroscience literature has related treatment with aripiprazole to improved memory performance and subcellular changes in the hippocampus.

AIMS:

To explore the volumetric changes in hippocampal grey matter in people with a first episode of psychosis (FEP) treated with second-generation antipsychotics.

METHOD:

Baseline and 1-year follow-up magnetic resonance images were obtained. Hippocampal volumes were estimated by using FreeSurfer and MAGeT-Brain. Subgroups included: aripiprazole (n=13), olanzapine (n=12), risperidone/paliperidone (n=24), refused-antipsychotics (n=13) and controls (n=44).

RESULTS:

Aripiprazole subgroup displayed significant increases in bilateral hippocampal volume compared with all other subgroups (FreeSurfer: all P's<0.012; MAGeT-Brain: all P's<0.040).

CONCLUSIONS:

Aripiprazole is a first-line, second-generation treatment option that may provide an added benefit of pro-hippocampal growth. The biological underpinnings of these changes should be the focus of future investigations and may be key towards achieving a better clinical outcome for more individuals.

DECLARATION OF INTEREST:

M.L. received financial assistance/compensation for research and educational events from Janssen-Ortho, Eli Lilly, Roche and Otsuka/Lundbeck Alliance. A.K.M. received financial assistance/compensation for research and educational activities from Pfizer, Janssen-Ortho, AstraZeneca and Bristol-Myers Squibb. R.J. received consultancy honorariums from Pfizer and Janssen-Ortho.

COPYRIGHT AND USAGE:

© The Royal College of Psychiatrists 2016. This is an open access article distributed under the terms of the Creative Commons Non-Commercial, No Derivatives (CC BY-NC-ND) licence.

Supplemental Content

Full text links

Icon for Cambridge University Press Icon for PubMed Central
Loading ...
Support Center